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ABSTRACT
To assess body proportions in girls with Turner syndrome (TS)
during long term GH treatment, height, sitting height (SH), hand
(Hand) and foot (Foot) lengths, and biacromial (Biac) and biiliacal
(Biil) diameters were measured in 68 girls with TS participating in a
GH dose-response trial. These previously untreated girls with TS,
aged 2–11 yr, were randomly assigned to 1 of 3 GH dosage groups:
group A, 4 IU/m2zday; group B, first year 4 and thereafter 6 IU/m2zday;
group C, first year 4, second year 6, and thereafter 8 IU/m2zday.
Seven-year data were evaluated to assess the effect of GH treatment
on body proportions during childhood. In addition, data from all girls
who had reached adult height were evaluated to determine the effect
on the adult body proportions. All results were adjusted for age and
sex and expressed as SD scores using reference values of healthy Dutch
girls. To describe the proportions of SH, Hand, Foot, Biac, and Biil to
height, these values were adjusted for the SD score of height and were
expressed as shape values, using the formula, e.g. for SH: shape SH 5
(SH SD score 2 height SD score)/=(2 2 2 3 correlation coefficient
between SH and height in the reference population). Furthermore, SD
scores using references of untreated girls with TS were calculated for
height and SH. Values less than 22 or more than 12 were considered
outside the normal range.
At baseline, the shape values of all measurements were signifi-
cantly higher than zero, but most mean shape values were still within
the normal range. Seven-year data of 64 girls and adult height data
of 32 girls showed that an increase in height was accompanied by an
even higher increase in Foot, resulting in mean SD scores above zero
and shape values of 12 and higher. The increase in the shape value
of Foot was significantly higher in groups B and C compared to that
in group A after 7 yr of GH treatment, but there were no significant
differences between the GH dosage groups in the girls who had
reached adult height. The shape values of SH had decreased to values
closer to zero after reaching adult height, especially in group A. A
similar pattern in the relationship of SH to height was seen using
references of girls with TS. No significant changes in the other pro-
portions were found after reaching adult height.
In conclusion, on the average, untreated girls with TS have relatively
large trunk, hands, and feet, and broad shoulders and pelvis compared
to height. The increase in height after long term GH treatment is ac-
companied by an even higher increase in Foot and a moderate improve-
ment of the disproportion between height and SH. Recently published
reference data from untreated adults with TS and the results of a dif-
ferent patient group receiving a comparable GH dosage suggest that the
disproportionate growth of feet has to be considered a part of the natural
development in TS, but might be influenced by higher GH dosages. The
development of large feet can play a role in the decision of the girl to
discontinue GH treatment in the last phase of growth. (J Clin Endocrinol
Metab 84: 4622–4628, 1999)
GROWTH FAILURE and subsequently short adult stat-ure are two of the main features in Turner syndrome
(TS) (1, 2). Although these girls are not clearly GH deficient
(3), GH administration accelerates growth in a dose-depen-
dent way (4–6). In addition, recent reports reported a con-
siderable increase in adult height in girls who started GH
treatment at a relatively young age (7–9).
The general clinical impression of body proportions of
untreated girls with TS is that these girls have a more coarse
and stocky figure compared to healthy girls. This is con-
firmed by earlier studies describing relatively short lower
extremities and relatively broad shoulders and pelvis (10–
12). Little is known about the effects of supraphysiological
GH dosages given for a long time during childhood. The
most remarkable reported changes in body proportions in TS
after 2 yr of GH treatment were an increase in pelvic width
and an increased length and breadth of hands and feet com-
pared to the increase in height (10, 13). Four-year data on
height and sitting height (SH) were described by Rongen et
al., demonstrating no change in proportion (14).
To determine the body proportions before, during, and
after long term GH treatment, we measured height, SH, hand
length (Hand), foot length (Foot), biacromial diameter (Biac),
and biiliacal diameter (Biil) in 68 girls with TS participating
in a randomized dose-response study. The effect on height
was described previously (15). We now report body propor-
tions during childhood, comparing 7-yr data from 3 GH
dosage groups. Data from all girls who have reached adult
height have been evaluated as well.
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Subjects and Methods
Sixty-eight previously untreated girls with TS were enrolled in a
multicenter GH dose-response study. The diagnosis was confirmed by
lymphocyte chromosomal analysis. Inclusion criteria were a chronolog-
ical age between 2–11 yr, height below the 50th percentile for healthy
Dutch girls (16), and normal thyroid function. Exclusion criteria were
associated endocrine and/or metabolic disorders, growth failure caused
by other disorders or emotional deprivation, hydrocephalus, previous
use of drugs that could interfere with GH treatment, and spontaneous
puberty (17). Written informed consent was obtained from the girls and
their parents or custodians. The study protocol was approved by the
ethics committee of each participating center.
Sixty-eight girls were approached, and after the randomization all
girls started GH treatment. After stratification for chronological age and
height sd score for chronological age girls were randomly assigned to
the following groups: group A (n 5 23), receiving 4 IU/m2 body
surfacezday (equivalent to 0.045 mg/kg); group B (n 5 23), receiving 4
IU/m2zday in the first year, followed by 6 IU/m2zday; and group C (n 5
22), receiving 4 IU/m2zday in the first year, 6 IU/m2zday in the second
year, and thereafter 8 IU/m2zday.
Biosynthetic human GH (Norditropin, Novo Nordisk A/S, Bags-
vaerd, Denmark) was given sc once daily at bedtime using a pen in-
jection system. Every 3 months the total GH dose was adjusted to the
calculated body surface. According to study protocol, treatment was
stopped when subjects had grown less than 1 cm over 6 months. After
the first 4 yr of the study period, girls started estrogen therapy when they
had reached the age of 12 yr. In the first 2 yr of estrogen therapy, the girls
received 5 mg 17b-estradiol/kg BWzday, in the third year they received
7.5 mg/kgzday, and thereafter they were given 10 mg/kgzday.
Height, SH, Hand (left), Foot (left), Biac, and Biil were measured at
baseline and subsequently every 6 months by two trained observers.
Measurements were taken according to the procedure of Cameron (18).
Height and SH were obtained using a Harpenden stadiometer and SH
table. The other measurements were taken with the Harpenden anthro-
pometer. Two measurements per visit were made, and the mean was
used for the analysis. The results of each measurement were adjusted for
age and sex and expressed as a sd score. When GH treatment was
stopped, the last available measurements at discontinuation of GH treat-
ment were considered the definite values, assuming that no change in
body proportions will take place after stopping GH treatment. For the
evaluation of body proportions in the girls after reaching adult height,
the reference values at the age of 18 yr were used for calculating the sd
scores. The data of the Oosterwolde Study were used as references for
healthy Dutch girls (19). This reference population consisted of 1093
Dutch girls, ranging from birth to 18 yr of age. To calculate sd scores,
data from the reference population were transformed using the LMS
method (20, 21). This method transforms the reference data at each age
to a normal distribution. In addition, the sd scores of the measurements
of SH, Hand, Foot, Biac, and Biil were adjusted for the height sd score
and expressed as the shape value. The shape value, in this example
defined as the SH sd score adjusted for the height sd score, was calcu-
lated using the formula (10, 22): shape SH 5 (SH sd score 2 height sd
score)/=(2 2 2r), in which r is the correlation coefficient between height
and SH in the reference population. Values less than 22 or more than
12 were considered outside the normal range.
Unfortunately, no reference values from untreated girls with TS were
available, except for height (Dutch-Swedish-Danish Turner references)
(2) and SH (Dutch Turner references) (12). Because the reference pop-
ulations for height and SH were not totally identical, and the correlation
coefficient between height and SH in girls with TS was not known, only
sd scores of both measurements were calculated using the reported
means and sds per yr. For the evaluation of body proportions in the girls
after reaching adult height, the Turner reference values at maximum
ages of 21 and 23 yr were used for calculating the Turner sd scores of
height and SH, respectively. Seven girls were of non-Caucasian origin
(3 in group A, 3 in group B, and 1 in group C). Although reference values
for body proportions of non-Caucasian girls might be somewhat dif-
ferent compared to our Caucasian references, all girls were included in
the statistical analysis. Pubertal stages were assessed according to the
method of Tanner (17).
Results are expressed as the mean (sd), unless indicated otherwise.
At baseline, after 7 yr, and after reaching adult height, sd scores and
shape values were compared with zero using Student’s one-sample t
tests. sd scores or shape values after 7 yr of GH treatment or after
reaching adult height were compared to baseline using paired Student’s
t tests. Differences in change in shape values between the GH dosage
groups were first tested by a linear trend test to assess a possible dose-
dependent effect. In case of a significant result, this was followed by
comparisons with Student’s two-sample t tests. An intention to treat
analysis was performed based on all available data. P , 0.05 was con-
sidered significant.
Results
The trial started in 1989. In October of 1997, all girls had
been followed for 7 yr. At the end of August 1998, 32 patients
had discontinued GH treatment. In each group 1girl dropped
out of the study long before reaching adult height for the
following reasons: noncompliance, presumed increase in
muscle mass and decline in school performance, and desire
to initiate estrogen therapy before the fourth year of GH
treatment. In another girl in group B no measurements of
body proportions were available after 4 yr of treatment.
Therefore, analysis of body proportions during long term
GH treatment was not possible in these four girls. Table 1 lists
the baseline clinical data of the remaining 64 girls as well as
those of the 32 girls who had discontinued GH treatment
after reaching (near) adult height. The 3 groups of patients
had similar initial characteristics.
7-yr evaluation
Figure 1 shows the sd scores of the measurements at base-
line and during 7 yr of GH treatment in groups A, B, and C,
respectively. At the start of GH treatment, all mean sd scores
were significantly lower than zero, indicating stunted
growth in several body parts. However, the baseline sd score
of height was lower than the sd scores of the other mea-
surements. After 7 yr of GH treatment all sd scores had
increased significantly compared to baseline. The sd scores
of height, SH, Biac, and Biil showed an increase, especially
in the first 4 yr of treatment, whereas the sd scores of Hand
and Foot demonstrated a sustained increase throughout the
entire study period up to values higher than zero in the
higher GH dosage groups.
The sd scores of height and SH using the Turner references
are presented in Fig. 2. At the start of treatment, height and
SH were not different from those in Turner controls, except
for SH in group B. After 7 yr, height and SH showed similar
TABLE 1. Mean (SD) baseline data for each treatment group.
Group A Group B Group C
Total group of girls
No. of girls 22 21 21
Chronological age (yr) 6.1 (2.1) 6.7 (2.5) 6.5 (2.4)
Ht SD score 22.9 (0.9) 22.8 (0.8) 22.7 (1.0)
Karyotype
45,X 18 (82%) 20 (95%) 16 (76%)
other 4 (18%) 1 (5%) 5 (24%)
32 girls who had reached (near) adult height
No. of girls 10 10 12
Chronological age (yr) 7.9 (0.9) 8.6 (1.6) 8.1 (1.4)
Ht SD score 22.9 (1.0) 23.0 (0.7) 23.0 (0.7)
Karyotype (45,X; other) is expressed as the number (percentage) of
patients.
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increases, suggesting no obvious change in body proportion
between height and SH.
Figure 3 shows the shape values at baseline and during 7
yr of treatment for groups A, B, and C. At the start of the
treatment all mean shape values were significantly higher
than zero, indicating a relatively large trunk, relatively large
hands and feet, and relatively broad shoulders and pelvis
compared to height. However, most shape values were
within the normal range. The shape values of SH and Biac
had not significantly changed over the 7 yr, whereas the
shape value of Biil had significantly decreased. The mean
shape values of Hand showed a decrease in the first years of
the study followed by an increase up to values around 12;
however, they were only statistically significant from base-
line in group C. The shape values of Foot increased signif-
icantly during treatment up to values 12 or greater in all
three GH dosage groups. Only the increase in shape value of
Foot was significantly higher in groups B and C compared
to that in group A, without a significant difference between
groups B and C.
Girls who remained prepubertal throughout the entire
study period (n 5 24) showed similar patterns in shape
values as the whole study group (data not shown).
Body proportions after reaching adult height
Thirty-two patients (groups A, B, and C; n 5 10, 10, and
12, respectively) have discontinued GH treatment after a
mean duration of treatment of 7.3 yr (1.1) (range, 5.0–8.5 yr).
Twenty girls had discontinued GH treatment because of a
height velocity less than 1 cm over 6 months, and 12 girls
stopped GH treatment in the last phase of growth because
they were satisfied with their attained height.
The baseline clinical data of these 32 girls were, except for
age, comparable with the baseline data of the total group of
64 girls (Table 1). At the last measurements, the mean (sd) age
was 15.6 (0.7) yr in group A, 15.2 (1.3) yr in group B, and 15.2
(0.9) yr in group C. Although, the duration of the GH treat-
ment (from baseline to the last measurement) seemed to be
shorter in groups B [6.7 (1.3)] and C [7.1 (1.2)] than in group
A [7.6 (0.7)], the linear trend test showed no significant dose-
dependent effect.
Table 2 shows the sd scores and shape values at the start
of treatment and at discontinuation of GH treatment. Base-
line values of these 32 girls were similar to those of the total
group of 64 girls. Except for the sd score of SH in group A,
all sd scores had significantly increased compared to base-
line. The largest increase in sd scores was seen in Hand and
FIG. 1. Mean (SD) SD scores using reference values from healthy Dutch girls at baseline and during 7 yr of GH treatment in groups A (black
bars), B (gray bars), and C (white bars), respectively. Significant differences from zero (1, P , 0.001; 2, P , 0.005; 3, P , 0.05) and significant
changes from baseline to 7 yr of GH treatment (a, P , 0.001) are indicated.
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Foot. In group C, Foot had increased to a mean value sig-
nificantly higher than that in healthy women. The shape
values of Biac and Biil showed no change compared to base-
line, whereas the shape value of SH had significantly de-
creased. The decrease in the shape value of SH was signif-
icant less in groups B and C than in group A. The mean shape
values of Hand deviated more toward abnormal high values;
however, these changes were not statistically significant. The
shape value of Foot had increased significantly to values
outside the normal range, without significant differences
between the GH dosage groups.
The sd scores of height using the Turner references had
significantly increased by 1.7 (0.5) in group A, 1.9 (0.6) in
group B, and 2.2 (0.7) in group C compared to baseline (P ,
0.001). The increase in the sd score of SH using Turner ref-
erences increased by 0.6 (0.5) in group A, 0.9 (0.4) in group
B, and 1.3 (0.7) in group C compared to baseline (P 5 0.004
for group A; P , 0.001 for groups B and C). Thus, the increase
in the Turner sd score for height seems to be higher than that
in the sd score for SH.
Discussion
The present study showed that untreated girls with TS,
between 2–11 yr of age, are short and have smaller hands and
feet and narrow shoulders and pelvis compared to healthy
peers. As height is more affected than other parts of the body,
untreated girls have, on the average, a relatively large trunk,
relatively large hands and feet, and relatively broad shoul-
ders and pelvis compared to height. Most shape values,
however, were within the normal range. Our data are in line
with the results reported by Gerver et al., describing higher
mean shape values in somewhat older girls (6–19 yr) with TS
(10). Zellner et al. demonstrated higher sd scores of Hand and
Foot than of height, indicating relatively large hands and feet
(13). Rongen et al. reported that especially younger girls with
TS have relatively short legs compared to trunk height (12).
During GH treatment all measured parts of the body in-
creased in size to values close to those in healthy peers or
even higher. The 7-yr data showed that the increase in SH
and Biac was comparable with that in height, resulting in no
change in shape values. Although we do not have shape
values for SH based on Turner references, our 7-yr Turner sd
scores also suggest no change in the proportion of SH to
height. The shape value of the Biil had decreased during the
7 yr to values more appropriate for height. Hand and Foot
showed a sustained increase in size throughout the entire
study period, resulting in mean sd scores above zero and
shape values approximately 12 or higher. Only the increase
in the shape value of Foot was dose dependent. Other studies
in girls with TS also reported a higher increase in the sd
scores of hand and foot than in that of height after 2 yr of GH
treatment (10, 13). Rongen et al. demonstrated, as we did, no
change in the preexisting disproportion between height and
SH during childhood after 4 ys of GH treatment (14). How-
ever, the biggest change in body proportions in the study of
Gerver et al. was the increased Biil compared to height after
2 yr of GH treatment (10). In our study, the shape value of
Biil decreased during 7 yr of GH treatment and was not
changed in the subgroup of girls who had reached adult
height. The discrepancy between the previously published
data and our data concerning Biil compared to height may
be caused by the good catch-up in height and the lesser
increase in Biil. Compared to the other measurements, the
measurement of Biil is higher influenced by the increase in
body fat, which is seen especially in adolescents and adults
with TS.
Thirty-two girls had reached their adult stature after long
term GH treatment. For the present study, we made the
assumption that no change in body proportions will take
place after stopping GH treatment. Our clinical impression
is that only some additional millimeters to a centimeter in
height can be achieved in the years after discontinuation of
FIG. 2. Mean (SD) SD scores of height and SH using the Turner references at baseline and during 7 yr of GH treatment in groups A (black bars),
B (gray bars), and C (white bars), respectively. Significant differences from zero (1, P , 0.001) and significant changes from baseline to 7 yr
of GH treatment (a, P , 0.001) are indicated.
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treatment after reaching (near) final height. However, we
assumed that the possible additional millimeters in height
will be accompanied by a similar increase in size of other
parts of the body after stopping GH treatment. Preliminary
data for older girls with TS obtained by our group seem to
confirm this assumption; however, follow-up of the girls in
the present study is required to substantiate this. The data
from the 32 girls showed no change in shape values of Biac
and Biil. Although the shape value of Hand had deviated
more from normal compared to baseline, the change was not
significant. In contrast, Foot had increased to mean values
equal to or higher than the mean value for healthy women
and shape values outside the normal range. However, no
significant differences between the GH dosage groups were
found. The shape value of SH showed a decrease to values
close to zero, especially in group A. The sd scores for height
and SH using Turner references showed the same pattern: a
higher increase in height than in SH. Thus, in the girls who
had reached adult height after long term GH treatment, the
disproportion between SH and height had improved, but the
proportion of Foot to height had worsened.
The cause and mechanism of the change in body propor-
tions after long term GH treatment in girls with TS are not
clear-cut. In our study, girls in group A received the usual
GH dose, but higher GH doses were given in groups B and
C. The 7-yr increase in shape value of Foot was dose depen-
dent, suggesting a GH-induced abnormality. In adults, ex-
cessive GH secretion can lead to acromegalic features, in-
cluding big hands and feet, which are caused by thickening
of the bone and surrounding soft tissue. Less is known about
the effects of high GH levels during childhood. Although we
did not include systematic radiographic measurements of
bone length and soft tissue in our study, we saw no obvious
soft tissue thickening on the standardized x-rays of the hand.
This suggests that in girls with TS the increase in the size of
the hands is caused by longitudinal growth of bone and does
not seem to be part of the acromegalic changes. In addition,
it has been reported that high GH levels in children during
the growth phase (gigantism; most common cause is an au-
tonomously functioning pituitary adenoma) result in pro-
portional growth in length and width of the bones (23). As
in most other studies, we did not include a randomized
control group receiving no GH treatment until adult height.
Unfortunately, no reference values for TS were available for
Hand, Foot, Biac, and Biil during the growth phase. There-
fore, we do not know the natural development of those body
proportions in untreated girls with TS during childhood.
However, recent reference values were reported for adult
FIG. 3. Mean (SD) shape values at baseline and during 7 yr of treatment for groups A (black bars), B (gray bars), and C (white bars), respectively.
Significantly differences from zero (1, P , 0.001; 2, P , 0.005) and significant changes from baseline to 7 yr of GH treatment (a, P , 0.001;
b, P , 0.005; c, P , 0.05) are indicated. Significant differences in the changes in shape value from baseline to 7 yr of GH treatment in this GH
dosage group compared to group A were also indicated (*, P , 0.05; **, P , 0.005).
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women with TS, who had received no GH therapy in child-
hood (24). To compare those data with ours, we calculated
the mean shape values from the sd scores of that study,
because the same reference population was used as in our
study. It was shown that untreated adult women with TS
have no disproportion between height and SH, but shape
values of Hand were even higher than those in our 32 girls
who had reached adult height. The mean shape value of Foot
in these women was as high as that in group A, but was lower
than those in groups B and C in our analysis of adult data.
The shape values for Biac and Biil were considerably higher
than our adult shape values. These reference data suggest
that the decrease in shape SH and the increase in shape
values for Hand and Feet found in our study are partly due
to the natural development of these body proportions in girls
with TS. As observed in forms of skeletal dysplasia, body
proportions may change during childhood. One might spec-
ulate that GH exaggerates this naturally occurring dispro-
portionate growth in girls with TS while they reach a normal
height. Remarkably, our data from a different patient group
receiving 6 IU GH/m2zday showed no abnormal growth of
hands and feet (Sas, T. C., W. J. Gerver, R. de Bruin, et al.,
submitted for publication). Because the increments in shape
values of Hand and Foot appeared mainly after the fourth
year, estrogen therapy was thought to be one of the causes
of the abnormal development of Hand and Foot. However,
the same pattern was seen in the girls without pubertal signs
and estrogen therapy throughout the study. Therefore, the
changes in body proportions could not be attributed to pu-
berty or estrogen therapy.
As described in previous reports, long term GH treatment
results in a height within the normal range in most girls with
TS (7, 15). In the present study we showed that the increase
in height is accompanied by abnormal growth of the feet,
resulting in relatively large feet for height as well as for age.
Especially in the last phase of growth, some girls in our study
complained about big feet. The possibility of additional foot
growth may have influenced their decision to discontinue
GH treatment before adult height was reached.
In conclusion, girls with TS have, on the average, a rela-
tively large trunk, hands, and feet, and broad shoulders and
pelvis compared to height. The increase in height after long
term GH treatment is accompanied by an even greater in-
crease in the size of the feet and a moderate improvement of
the disproportion between height and SH. Recent published
reference data for adults with TS and results of a different
GH-treated patient group suggest that the disproportionate
growth of feet is part of the natural development in TS, but
might be influenced by higher GH dosages.
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